AP125A - Pharmaceutical compositions for the regeneration of leukocytes and their use in the treatment of aquired immuno-deficiency syndrome - Google Patents

Pharmaceutical compositions for the regeneration of leukocytes and their use in the treatment of aquired immuno-deficiency syndrome Download PDF

Info

Publication number: AP125A
Authority: AP; ARIPO
Prior art keywords: tetrahydroacridine; pharmaceutical compositions; group; amino; lymphocytes
Prior art date: 1988-12-19

Application number

APAP/P/1990/000157A

Other languages

English (en)

Other versions

AP8900157A0 (en

Inventor

Francois Deitlin

Daniéle Fredj

Original Assignee

S C R Newpharm

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-12-19

Filing date

1989-12-18

Publication date

1991-03-19

1989-12-18 Application filed by S C R Newpharm filed Critical S C R Newpharm

1990-01-31 Publication of AP8900157A0 publication Critical patent/AP8900157A0/xx

1991-03-19 Application granted granted Critical

1991-03-19 Publication of AP125A publication Critical patent/AP125A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
230000008929 regeneration Effects 0.000 title claims description 5
238000011069 regeneration method Methods 0.000 title claims description 5
208000033065 inborn errors of immunity Diseases 0.000 title abstract 2
208000028529 primary immunodeficiency disease Diseases 0.000 title abstract 2
210000000265 leukocyte Anatomy 0.000 title description 2
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims abstract description 21
239000002243 precursor Substances 0.000 claims abstract description 12
150000001875 compounds Chemical class 0.000 claims abstract description 11
239000004480 active ingredient Substances 0.000 claims abstract description 9
239000003443 antiviral agent Substances 0.000 claims abstract description 9
150000003839 salts Chemical class 0.000 claims abstract description 9
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims abstract description 6
239000002253 acid Substances 0.000 claims abstract description 6
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims abstract description 5
238000000034 method Methods 0.000 claims abstract description 5
231100000252 nontoxic Toxicity 0.000 claims abstract description 5
230000003000 nontoxic effect Effects 0.000 claims abstract description 5
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims abstract description 4
239000003937 drug carrier Substances 0.000 claims abstract description 3
239000012458 free base Substances 0.000 claims abstract description 3
239000003981 vehicle Substances 0.000 claims abstract description 3
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims abstract 2
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims abstract 2
229940045145 uridine Drugs 0.000 claims abstract 2
210000004698 lymphocyte Anatomy 0.000 claims description 13
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 7
239000000787 lecithin Substances 0.000 claims description 7
235000010445 lecithin Nutrition 0.000 claims description 7
229940067606 lecithin Drugs 0.000 claims description 7
208000011580 syndromic disease Diseases 0.000 claims description 5
125000002252 acyl group Chemical group 0.000 claims description 3
125000001931 aliphatic group Chemical group 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
150000004646 arylidenes Chemical group 0.000 claims description 2
QPAARLKPLQNQBS-UHFFFAOYSA-N 1,2,3,4-tetrahydroacridin-1-amine Chemical compound C1=CC=C2C=C3C(N)CCCC3=NC2=C1 QPAARLKPLQNQBS-UHFFFAOYSA-N 0.000 claims 1
FLTVDXBUZLYLDW-UHFFFAOYSA-N 9-benzylidene-2,3,4,9a-tetrahydroacridin-1-imine Chemical compound C(C1=CC=CC=C1)=C1C2=CC=CC=C2N=C2CCCC(C12)=N FLTVDXBUZLYLDW-UHFFFAOYSA-N 0.000 claims 1
WBLGDOQKTYVVGF-UHFFFAOYSA-N 9-propan-2-ylidene-2,3,4,9a-tetrahydroacridin-1-imine Chemical compound C(C)(C)=C1C2=CC=CC=C2N=C2CCCC(C12)=N WBLGDOQKTYVVGF-UHFFFAOYSA-N 0.000 claims 1
150000001735 carboxylic acids Chemical class 0.000 claims 1
208000024891 symptom Diseases 0.000 abstract description 4
238000011084 recovery Methods 0.000 abstract description 2
238000002560 therapeutic procedure Methods 0.000 abstract description 2
230000001172 regenerating effect Effects 0.000 abstract 2
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
239000002547 new drug Substances 0.000 abstract 1
229940035893 uracil Drugs 0.000 abstract 1
-1 alkyl radicals Chemical class 0.000 description 10
LXHOFEUVCQUXRZ-RRKCRQDMSA-N 6-azathymidine Chemical compound O=C1NC(=O)C(C)=NN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LXHOFEUVCQUXRZ-RRKCRQDMSA-N 0.000 description 7
241000862632 Soja Species 0.000 description 5
208000030507 AIDS Diseases 0.000 description 4
230000007423 decrease Effects 0.000 description 4
239000003826 tablet Substances 0.000 description 4
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
239000002775 capsule Substances 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
RXBYRTSOWREATF-UHFFFAOYSA-N 1,2,3,4-tetrahydroacridine Chemical compound C1=CC=C2C=C(CCCC3)C3=NC2=C1 RXBYRTSOWREATF-UHFFFAOYSA-N 0.000 description 2
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000000725 suspension Substances 0.000 description 2
JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
GOWMBYUZXIZENX-CAUSLRQDSA-N 1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(hexadecylamino)pyrimidin-2-one Chemical compound O=C1N=C(NCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 GOWMBYUZXIZENX-CAUSLRQDSA-N 0.000 description 1
ZEIYLROOZCYYKO-UHFFFAOYSA-N 1-benzylidene-2,3,4,9a-tetrahydroacridin-9-imine Chemical compound C(C1=CC=CC=C1)=C1CCCC2=NC3=CC=CC=C3C(C12)=N ZEIYLROOZCYYKO-UHFFFAOYSA-N 0.000 description 1
FGBRUIVBHMUQPM-UHFFFAOYSA-N 1-methylidene-2,3,4,9a-tetrahydroacridin-9-imine Chemical compound C=C1CCCC2=NC3=CC=CC=C3C(C12)=N FGBRUIVBHMUQPM-UHFFFAOYSA-N 0.000 description 1
RTHHTTRUEGUKEF-UHFFFAOYSA-N 1-propan-2-ylidene-2,3,4,9a-tetrahydroacridin-9-imine Chemical compound N=C1C2=CC=CC=C2N=C2CCCC(C12)=C(C)C RTHHTTRUEGUKEF-UHFFFAOYSA-N 0.000 description 1
HZNQSWJZTWOTKM-UHFFFAOYSA-N 2,3,4-trimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C(OC)=C1OC HZNQSWJZTWOTKM-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000700605 Viruses Species 0.000 description 1
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
RWHOZGRAXYWRNX-VFUOTHLCSA-N alpha-D-glucose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H](OP(O)(O)=O)[C@@H]1O RWHOZGRAXYWRNX-VFUOTHLCSA-N 0.000 description 1
HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000002647 anti-cholinesterasic effect Effects 0.000 description 1
239000000729 antidote Substances 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
229930183167 cerebroside Natural products 0.000 description 1
RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
229940114119 gentisate Drugs 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229950010772 glucose-1-phosphate Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
239000007887 hard shell capsule Substances 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012961 medicinal therapy Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000000842 neuromuscular blocking agent Substances 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229960001685 tacrine Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
235000008979 vitamin B4 Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

APAP/P/1990/000157A 1988-12-19 1989-12-18 Pharmaceutical compositions for the regeneration of leukocytes and their use in the treatment of aquired immuno-deficiency syndrome AP125A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR888816749A FR2640508B1 (fr)	1988-12-19	1988-12-19	Nouvelles compositions et nouveaux produits pharmaceutiques assurant la regeneration de leucocytes et leur emploi pour le traitement du syndrome immuno-deficitaire

Publications (2)

Publication Number	Publication Date
AP8900157A0 AP8900157A0 (en)	1990-01-31
AP125A true AP125A (en)	1991-03-19

Family

ID=9373109

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1990/000157A AP125A (en)	1988-12-19	1989-12-18	Pharmaceutical compositions for the regeneration of leukocytes and their use in the treatment of aquired immuno-deficiency syndrome

Country Status (19)

Country	Link
EP (1)	EP0375471B1 (fr)
JP (1)	JPH02258722A (fr)
KR (1)	KR900009075A (fr)
AP (1)	AP125A (fr)
AT (1)	ATE136463T1 (fr)
AU (2)	AU4686189A (fr)
CA (1)	CA2005925C (fr)
DE (1)	DE68926222D1 (fr)
DK (1)	DK646489A (fr)
FR (1)	FR2640508B1 (fr)
HU (1)	HU213510B (fr)
IL (1)	IL92759A (fr)
MA (1)	MA21964A1 (fr)
MY (1)	MY106032A (fr)
NZ (1)	NZ231854A (fr)
OA (1)	OA09250A (fr)
PT (1)	PT92620B (fr)
TN (1)	TNSN89135A1 (fr)
ZA (1)	ZA899733B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5155226A (en) *	1991-02-19	1992-10-13	Hoechst-Roussel Pharmaceuticals Incorporated	Method for the preparation of 9-amino-1,2,3,4-tetrahydroacridine
EP0509401A1 (fr) *	1991-04-19	1992-10-21	Hoechst-Roussel Pharmaceuticals Incorporated	Utilisation de 9-amino-1,2,3,4-tetrahydroacridine-1-ol et des composés apparentés pour le traitement du SIDA
RU2036198C1 (ru) *	1993-04-01	1995-05-27	Товарищество с ограниченной ответственностью "Полисан"	N-МЕТИЛ-N-( α,D -ГЛЮКОПИРАНОЗИЛ) АММОНИЯ-2-(АКРИДОН-9-ОН-10-ИЛ)АЦЕТАТ(ЦИКЛОФЕРОН), ОБЛАДАЮЩИЙ ИНТЕРФЕРОНОГЕННОЙ, ПРОТИВОВИРУСНОЙ, В ТОМ ЧИСЛЕ АНТИВИЧ, АНТИПАРАЗИТАРНОЙ, АНТИПРОМОТОРНОЙ И РАДИОПРОТЕКТИВНОЙ АКТИВНОСТЬЮ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0319429A2 (fr) *	1987-12-03	1989-06-07	Mitsubishi Kasei Corporation	Dérivés de la 9-(acylamino)tétrahydroacridine et agents pour l'amélioration de la mémoire les contenant comme ingrédient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4916122A (en) *	1987-01-28	1990-04-10	University Of Georgia Research Foundation, Inc.	3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
JPH02500364A (ja) *	1986-11-21	1990-02-08	マツクス‐プランク‐ゲゼルシヤフト　ツール　フエルデルング　デル　ヴイツセンシヤフテン　エー　フアウ	ヒトにおけるウイルス感染の治療法およびそのための組成物
IL86009A (en) *	1987-04-10	1991-09-16	Us Health	Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases
US5013741A (en) *	1987-09-08	1991-05-07	Hoechst-Roussel Pharmaceuticals Incorporated	N-[substituted alkylidene]-1,2,3,4-tetrahydro-9-acridinamines useful for enhancing the cholinergic function in a mammal
CH678275A5 (fr) *	1989-05-25	1991-08-30	Debiopharm Sa
US4999358A (en) *	1989-06-26	1991-03-12	Hoechst-Roussel Pharmaceuticals Inc.	(1,2,3,4-tetrahydro-9-acridinimino)cyclohexane carboxylic acid and related compounds
US4999430A (en) *	1989-07-31	1991-03-12	Warner-Lambert Company	Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine

1988
- 1988-12-19 FR FR888816749A patent/FR2640508B1/fr not_active Expired - Fee Related
1989
- 1989-09-29 DE DE68926222T patent/DE68926222D1/de not_active Expired - Lifetime
- 1989-09-29 EP EP89402687A patent/EP0375471B1/fr not_active Expired - Lifetime
- 1989-09-29 AT AT89402687T patent/ATE136463T1/de not_active IP Right Cessation
- 1989-12-18 IL IL9275989A patent/IL92759A/en not_active IP Right Cessation
- 1989-12-18 AP APAP/P/1990/000157A patent/AP125A/en active
- 1989-12-18 MA MA21958A patent/MA21964A1/fr unknown
- 1989-12-18 MY MYPI89001798A patent/MY106032A/en unknown
- 1989-12-19 NZ NZ231854A patent/NZ231854A/xx unknown
- 1989-12-19 OA OA59701A patent/OA09250A/fr unknown
- 1989-12-19 PT PT92620A patent/PT92620B/pt not_active IP Right Cessation
- 1989-12-19 ZA ZA899733A patent/ZA899733B/xx unknown
- 1989-12-19 KR KR1019890019125A patent/KR900009075A/ko not_active Ceased
- 1989-12-19 CA CA002005925A patent/CA2005925C/fr not_active Expired - Fee Related
- 1989-12-19 HU HU896683A patent/HU213510B/hu not_active IP Right Cessation
- 1989-12-19 JP JP1329377A patent/JPH02258722A/ja active Pending
- 1989-12-19 TN TNTNSN89135A patent/TNSN89135A1/fr unknown
- 1989-12-19 AU AU46861/89A patent/AU4686189A/en not_active Abandoned
- 1989-12-19 DK DK646489A patent/DK646489A/da not_active Application Discontinuation
1993
- 1993-05-25 AU AU39806/93A patent/AU666725B2/en not_active Expired - Fee Related

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0319429A2 (fr) *	1987-12-03	1989-06-07	Mitsubishi Kasei Corporation	Dérivés de la 9-(acylamino)tétrahydroacridine et agents pour l'amélioration de la mémoire les contenant comme ingrédient

Also Published As

Publication number	Publication date
CA2005925C (fr)	2002-03-26
PT92620B (pt)	1995-09-12
IL92759A0 (en)	1990-09-17
TNSN89135A1 (fr)	1991-02-04
EP0375471A2 (fr)	1990-06-27
DK646489A (da)	1990-06-20
FR2640508B1 (fr)	1994-07-01
OA09250A (fr)	1992-06-30
AU4686189A (en)	1990-06-21
CA2005925A1 (fr)	1990-06-19
PT92620A (pt)	1990-06-29
EP0375471A3 (fr)	1992-07-08
HU896683D0 (en)	1990-02-28
FR2640508A1 (fr)	1990-06-22
AP8900157A0 (en)	1990-01-31
EP0375471B1 (fr)	1996-04-10
DK646489D0 (da)	1989-12-19
JPH02258722A (ja)	1990-10-19
DE68926222D1 (de)	1996-05-15
HU213510B (en)	1997-07-28
ZA899733B (en)	1991-04-24
MA21964A1 (fr)	1991-07-01
AU3980693A (en)	1993-08-19
KR900009075A (ko)	1990-07-02
IL92759A (en)	1994-06-24
NZ231854A (en)	1993-01-27
MY106032A (en)	1995-02-28
ATE136463T1 (de)	1996-04-15
AU666725B2 (en)	1996-02-22

Publication	Publication Date	Title
CA2179521C (fr)	2002-03-19	2,4-disulfonyl phenyl butyl nitrone, ses sels et leur utilisation comme produits pharmaceutiques
CA1238277A (fr)	1988-06-21	Nucleosides antiviraux
JP2540576B2 (ja)	1996-10-02	抗レトロウイルスおよびｂ型肝炎剤
US5026716A (en)	1991-06-25	Method of treatment of anxiety and anxio-depressive disorders
AP125A (en)	1991-03-19	Pharmaceutical compositions for the regeneration of leukocytes and their use in the treatment of aquired immuno-deficiency syndrome
JPH02243666A (ja)	1990-09-27	ニューモシスティス・カリニ肺炎などの疾病の治療法および予防法そしてこれらの方法に用いる化合物および処方物
US20040171636A1 (en)	2004-09-02	Treatment of viral infections
EP1210116B1 (fr)	2007-01-03	Combnation d'un bloqueur des canaux de clcium et d'un quinoline pour le traitment d'infections virales
US3979511A (en)	1976-09-07	Inhibitors of reverse transcriptase enzymes
US5541212A (en)	1996-07-30	Use of cimetidine for the control of retrovirus infections
KR930000049B1 (ko)	1993-01-06	세트랄린을 사용한 화학약품 의존성의 치료방법
JPS61257925A (ja)	1986-11-15	抗ウイルスヌクレオシド
US5886000A (en)	1999-03-23	Anti-HIV agent
US5278167A (en)	1994-01-11	6-pyridyl substituted pyrimidine derivatives
EP0555302A1 (fr)	1993-08-18	Procede de traitement des maladies demyelinisantes
EP0697215A1 (fr)	1996-02-21	Substance reductrice des symptomes de troubles digestifs
AU2025205507A1 (en)	2026-02-12	A protease inhibitor and the pharmaceutical salt thereof
CA1340519C (fr)	1999-04-27	Nucleosides antiviraux
JPWO1995020388A1 (ja)	1996-06-25	抗ｈｉｖ剤
IL85096A (en)	1994-02-27	Use of 3'-azido-3'- deoxythymidine in the treatment of prophylaxis of human retrovirus infection
WO1989002741A1 (fr)	1989-04-06	Inhibiteurs de la transcriptase inverse de l'hiv servant au traitement du sida
WO1989002741A2 (fr)	1989-04-06	Inhibiteurs de la transcriptase inverse de l'hiv servant au traitement du sida